| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2020-02-10 | CELGENE CORP /DE/ | BeiGene, Ltd. | 32,746,416 | 4.2% | EDGAR |
| SC 13G | 2020-02-10 | CELGENE CORP /DE/ | SUTRO BIOPHARMA, INC. | 1,726,197 | 7.5% | EDGAR |
| SC 13G | 2019-05-30 | CELGENE CORP /DE/ | IDEAYA Biosciences, Inc. | 1,633,253 | 8.4% | EDGAR |
| SC 13G/A | 2019-02-11 | VANGUARD GROUP INC | CELGENE CORP /DE/ | 52,557,183 | 7.5% | EDGAR |
| SC 13G/A | 2019-02-04 | BlackRock Inc. | CELGENE CORP /DE/ | 53,650,909 | 7.7% | EDGAR |
| SC 13D/A | 2019-01-22 | CELGENE CORP /DE/ | ACCELERON PHARMA INC | 6,863,664 | 13.3% | EDGAR |
| SC 13D/A | 2018-03-05 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 99,227,867 | 85.4% | EDGAR |
| SC 13D/A | 2018-02-22 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2018-02-21 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2018-02-14 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2018-02-08 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 2,800,772 | 6.1% | EDGAR |
| SC 13G/A | 2018-02-08 | VANGUARD GROUP INC | CELGENE CORP /DE/ | 55,502,167 | 7.0% | EDGAR |
| SC 13D/A | 2018-02-02 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13G/A | 2018-01-29 | BlackRock Inc. | CELGENE CORP /DE/ | 54,614,215 | 6.9% | EDGAR |
| SC 13D/A | 2018-01-22 | CELGENE CORP /DE/ | Juno Therapeutics, Inc. | 11,109,160 | 9.7% | EDGAR |
| SC 13D/A | 2017-12-26 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 3,306,819 | 8.1% | EDGAR |
| SC 13G/A | 2017-12-08 | CELGENE CORP /DE/ | Atara Biotherapeutics, Inc. | 1,154,540 | - | EDGAR |
| SC 13D/A | 2017-12-06 | CELGENE CORP /DE/ | CRISPR Therapeutics AG | 3,722,534 | 9.1% | EDGAR |
| SC 13D/A | 2017-09-25 | CELGENE CORP /DE/ | ACCELERON PHARMA INC | 6,157,458 | 13.9% | EDGAR |
| SC 13G | 2017-09-01 | CELGENE CORP /DE/ | BeiGene, Ltd. | 32,746,416 | 5.6% | EDGAR |